Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study.
详细信息 查看全文
- 作者：Hiroshi Imaokaa ; hiroshi.imaoka.md@me.com" class="auth_mail" title="E-mail the corresponding author ; Tadayuki Koub ; Masao Tanakac ; Shinichi Egawad ; Nobumasa Mizunoa ; Susumu Hijiokaa ; Kazuo Haraa ; Shujiro Yazumib ; Yasuhiro Shimizue ; Kenji Yamaoa
- 关键词：Elderly patients ; Pancreatic cancer ; Gemcitabine ; S-1 ; Subgroup analysis
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：February 2016
- 年：2016
- 卷：54
- 期：Complete
- 页码：96-103
- 全文大小：434 K
文摘
- •
We performed a subgroup analysis from a randomised phase III trial, the GEST study.
- •
Gemcitabine plus S-1 (GS), S-1, and gemcitabine treatment resulted in similar overall survival.
- •
Severe adverse haematological events were more frequent with GS treatment.
- •
Three treatment-related deaths were observed in elderly GS-treated patients.